197 related articles for article (PubMed ID: 33605031)
1. A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment.
Miyagaki T; Okano T; Nakajima K; Mitsuishi S; Kishi A; Miyano K; Takeuchi S; Kadono T
Dermatol Ther; 2021 Mar; 34(2):e14888. PubMed ID: 33605031
[No Abstract] [Full Text] [Related]
2. Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
Kurihara K; Fujiyama T; Tokura Y; Honda T
Eur J Dermatol; 2021 Oct; 31(5):658-660. PubMed ID: 34704949
[No Abstract] [Full Text] [Related]
3. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
[TBL] [Abstract][Full Text] [Related]
4. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kabashima K; Oda M; Nagata T
J Am Acad Dermatol; 2021 Oct; 85(4):854-862. PubMed ID: 34118298
[TBL] [Abstract][Full Text] [Related]
5. Facial erythema during dupilumab treatment for atopic dermatitis successfully remedied with topical crisaborole ointment: A case report.
Tsai YC; Tsai TF
Dermatol Ther; 2022 Nov; 35(11):e15843. PubMed ID: 36124378
[No Abstract] [Full Text] [Related]
6. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study.
Nakagawa H; Igarashi A; Saeki H; Kabashima K; Tamaki T; Kaino H; Miwa Y
Allergol Int; 2024 Jan; 73(1):137-142. PubMed ID: 37100717
[TBL] [Abstract][Full Text] [Related]
7. Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis.
Suehiro M; Numata T; Murakami E; Takahashi M; Saito R; Morioke S; Kamegashira A; Takahagi S; Hide M; Tanaka A
Dermatol Ther; 2022 Jul; 35(7):e15526. PubMed ID: 35441769
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort.
Ordóñez-Rubiano MF; Casas M; Balaguera-Orjuela V
Dermatol Ther; 2021 Nov; 34(6):e15140. PubMed ID: 34549488
[TBL] [Abstract][Full Text] [Related]
9. Exosomes derived from human adipose tissue-derived mesenchymal stem cells for the treatment of dupilumab-related facial redness in patients with atopic dermatitis: A report of two cases.
Park KY; Han HS; Park JW; Kwon HH; Park GH; Seo SJ
J Cosmet Dermatol; 2022 Feb; 21(2):844-849. PubMed ID: 33844417
[TBL] [Abstract][Full Text] [Related]
10. A rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis.
Rao M; Grove D; Haggstrom A
Pediatr Dermatol; 2022 Mar; 39(2):288-290. PubMed ID: 35243667
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report.
Uchida H; Kamata M; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Acta Derm Venereol; 2019 Jun; 99(7):675-676. PubMed ID: 30938821
[No Abstract] [Full Text] [Related]
12. A case of dirty neck in severe and diffuse atopic dermatitis successfully treated with dupilumab.
Patruno C; Ferrillo M; Fabbrocini G; Napolitano M
Dermatol Ther; 2021 Jan; 34(1):e14556. PubMed ID: 33205854
[No Abstract] [Full Text] [Related]
13. English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021.
Saeki H; Ohya Y; Furuta J; Arakawa H; Ichiyama S; Katsunuma T; Katoh N; Tanaka A; Tsunemi Y; Nakahara T; Nagao M; Narita M; Hide M; Fujisawa T; Futamura M; Masuda K; Matsubara T; Murota H; Yamamoto-Hanada K
J Dermatol; 2022 Oct; 49(10):e315-e375. PubMed ID: 35996152
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
[TBL] [Abstract][Full Text] [Related]
15. A case of atopic dermatitis-associated dupilumab-resistant alopecia totalis successfully treated with baricitinib.
Seo T; Izumi K; Kawamura T; Tsujiwaki M; Ujiie H
Dermatol Ther; 2022 Dec; 35(12):e15953. PubMed ID: 36269309
[No Abstract] [Full Text] [Related]
16. Dupilumab facial redness: histologic characterization on a series of four cases.
Dybała A; Sernicola A; Gomes V; Carnicelli G; Muharremi R; Grieco T
Immunotherapy; 2022 Mar; 14(4):183-188. PubMed ID: 34933583
[TBL] [Abstract][Full Text] [Related]
17. Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
Anagawa-Nakamura A; Ryoke K; Yasui Y; Shoda T; Sugai S
Toxicol Pathol; 2020 Dec; 48(8):1008-1016. PubMed ID: 33334258
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment.
Nahum Y; Mimouni M; Livny E; Bahar I; Hodak E; Leshem YA
Br J Ophthalmol; 2020 Jun; 104(6):776-779. PubMed ID: 31554632
[TBL] [Abstract][Full Text] [Related]
19. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
Lor M; Villa N; Holland V
Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
[TBL] [Abstract][Full Text] [Related]
20. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
[No Abstract] [Full Text] [Related]
[Next] [New Search]
